The Age of Personalized Medicine: Trends and Opportunities Reflected in the U.S. Experience

Foley and ChinaBio invite you to join us for our upcoming executive workshop, which will explore this paradigm shift toward personalized medicine and its global implications for China’s life sciences business executives, health care professionals, and academic researchers.

Zu den zu diskutierenden Themen gehören:

• Business and social factors driving the move to personalized medicine, including non-sustainable medical costs, a decline in pharma R&D productivity, and the rise of patient-oriented health care


• Regulatory and intellectual property challenges to formulating a viable business model in the personalized medicine arena


• Potential for strategic collaborations with U.S. companies focused on different aspects of personalized medicine, such as genomic sequencing, biomarker substantiation, genetic testing, and electronic health records


• Post-grant patent issues, reducing patent litigation cost, and other risk management issues in the United States

Bestätigte Redner

• Andrew S. Baluch, Special Counsel, Intellectual Property Department and China Practice, Foley & Lardner LLP


• Nathan A. Beaver, Partner, Life Sciences Industry Team, Foley & Lardner LLP


• Song (Max) Lin, China Associate, Chemical, Biotechnology & Pharmaceutical Practice, Foley & Lardner LLP


• Alex Y. Nie, Associate, Chemical, Biotechnology & Pharmaceutical Practice and Life Sciences Industry Team, Foley & Lardner LLP


• Greg B. Scott, President and Founder, ChinaBio LLC

This workshop is complimentary; however, due to seating limitations, pre-registration is required. An acknowledgement email will be sent upon receipt of your registration request.

For more information, contact Delia Dai at [email protected] or 001.312.832.4506, or Emily Zhang at [email protected] or 86.21.5137.0751, ext. 20.